Microbiome R&D Center, Lactomason, Seoul, Republic of Korea.
Global Medical Research Center, Seoul, Republic of Korea.
J Cosmet Dermatol. 2024 Sep;23(9):2943-2955. doi: 10.1111/jocd.16357. Epub 2024 May 29.
Androgenetic alopecia (AGA) is a common and chronic problem characterized by hair follicle miniaturization.
In this study, heat-treated Limosilactobacillus fermentum LM1020 (HT-LM1020) was investigated in human follicle dermal papilla cell (HFDPC), scalp tissue, and clinical trials for patients with AGA.
PATIENTS/METHODS: Cell proliferation and the expression of cyclins and cyclin-dependent kinases (CDKs) were measured in HFDPC. The relative gene expression of 5α-reductase and growth factors were investigated in hair scalp. This double-blind, randomized, placebo-controlled clinical trial was conducted over 24 weeks. Primary efficacy was evaluated by measuring hair density, and secondary efficacy was assessed by experts and self-assessment. Changes in the microbiota of the hair scalps were analyzed using 16S metagenome amplicon sequencing.
HT-LM1020 promoted cell growth (p < 0.001) and cyclin B1 expression, and it reduced 5α-reductase and induced fibroblast growth factor 7 (FGF7), FGF10, and epithelial growth factor7 (EGF7) (p < 0.001). In the clinical trial, the experimental group demonstrated an increase in hair density from 133.70 to 148.87 n/cm at Week 24 (p < 0.001), while also expressing satisfaction with their hair density, reduced hair loss, and hairline. At Week 24, the total ratio of lactic acid bacteria operational taxonomic unit (OTU) in the scalp increased from 6.65% to 26.19%. At the same period, placebo-controlled group decreased Staphylococcus caprae OTU from 77.95% to 14.57% while experimental group decreased from 65.80% to 41.02%.
These present results showed that HT-LM1020 was a co-effector of ingredients for anti-hair loss contributing to cell proliferation and the expression of CDKs.
雄激素性脱发(AGA)是一种常见的慢性问题,其特征是毛囊小型化。
本研究旨在探讨热处理的嗜酸乳杆菌 LM1020(HT-LM1020)在人毛囊真皮乳头细胞(HFDPC)、头皮组织和 AGA 患者的临床试验中的作用。
患者/方法:在 HFDPC 中测量细胞增殖和细胞周期蛋白及细胞周期蛋白依赖性激酶(CDKs)的表达。在头发头皮中研究 5α-还原酶和生长因子的相对基因表达。这是一项为期 24 周的双盲、随机、安慰剂对照临床试验。主要疗效通过测量头发密度来评估,次要疗效由专家和自我评估来评估。使用 16S 宏基因组扩增子测序分析头皮微生物组的变化。
HT-LM1020 促进细胞生长(p<0.001)和细胞周期蛋白 B1 的表达,降低 5α-还原酶,并诱导成纤维细胞生长因子 7(FGF7)、FGF10 和表皮生长因子 7(EGF7)(p<0.001)。在临床试验中,实验组从第 24 周的 133.70 增加到 148.87 n/cm2(p<0.001),同时对头发密度、减少脱发和发际线表示满意。第 24 周时,头皮乳酸细菌操作分类单位(OTU)的总比例从 6.65%增加到 26.19%。同期,安慰剂对照组的山羊葡萄球菌 OTU 从 77.95%下降到 14.57%,实验组从 65.80%下降到 41.02%。
这些结果表明,HT-LM1020 是一种抗脱发成分的协同因子,有助于细胞增殖和 CDK 的表达。